No evidence of fluctuations in daily step count between infusions in people with multiple sclerosis treated with anti-CD20 monoclonal antibodies.

Valerie J Block, Kyra Henderson, Shane Poole, Gabby B Joseph, Jeffrey M Gelfand, Bruce Ac Cree, Riley Bove

Abstract read

In one paragraph

Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Digital signatures of fatigue and wearing-off symptoms in patients with multiple sclerosis under natalizumab.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Valerie J BlockDepartment of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA; Department of Physical Therapy and Rehabilitation Science, University of California, San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0001-6199-5484

Kyra HendersonDepartment of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.

Shane PooleDepartment of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-3203-151X

Gabby B JosephDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.

Jeffrey M GelfandDepartment of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.

Bruce Ac CreeDepartment of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0001-7689-2533

Riley BoveDepartment of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-2034-8800

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with multiple sclerosis (MS) on some disease-modifying therapies (i.e., natalizumab), report a "wearing-off" effect characterized by increased symptoms directly before infusions. Prior research suggests this may reflect natural MS fluctuations rather than true treatment waning; however, this has not been confirmed for anti-CD20 agents (e.g., ocrelizumab). Daily step count (STEPS) can reflect overall function. This study examined temporal associations between anti-CD20 therapy infusions and STEPS. Methods: Retrospective analysis evaluated data from two Fitbit-monitored cohorts ( Results: No significant difference in STEPS was observed pre- versus post-infusion ( Conclusions: This study found no evidence of an association between timing of anti-CD20 infusion and changes in STEPS. Findings highlight the need for integrating objective measures with patient-reported outcomes and biomarkers in future research to better understand potential treatment fluctuations.

Indexed as

activity monitoringanti-CD20 monoclonal antibodiesMultiple sclerosisphysical activityself-reported wearing offstep count

Identifiers

PMID40144903

DOI10.1177/20552173251329817

PMCPMC11938510

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.